Protective effects of influenza B neuraminidase antibodies against symptomatic influenza virus infection

Clicks: 1
ID: 320560
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #422 of 430 articles by views in The Journal of infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 430 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Influenza vaccines are designed to induce hemagglutinin-inhibiting (HAI) antibodies rather than neuraminidase-inhibiting (NAI) antibodies; therefore, NAI antibodies’ protective effects need further investigation. NAI antibodies’ protective effects, independent of HAI antibodies, have been demonstrated for influenza A viruses, but not influenza B viruses (IBV). Methods Employing H6NB reassortant virus targets, we evaluated NAI antibodies’ protective effects against IBV in sera from a prospective influenza vaccine effectiveness study among healthcare personnel (HCP) in Israel. Antibody titers against B/Brisbane/60/2008 and B/Phuket/3073/2013 were quantified by HAI and NAI assays. Matched NAI and HAI antibody titers from baseline and post-vaccination sera were analyzed for the 2017-2018 influenza season. Results Laboratory-confirmed IBV infection was recorded in 64/262 HCP, and influenza vaccination in 187/262 HCP. Vaccination did not consistently elicit rising NAI titers against vaccine strain B/Brisbane, with a geometric mean fold rise of 1.1 (95% CI: 0.9, 1.3). However, comparing baseline NAI titers, geometric mean titer ratios were 1.50 (95% CI: 1.0, 2.1) times higher against B/Brisbane and 2.5 (95% CI: 1.7, 3.6) times higher against circulating B/Phuket in vaccinated versus unvaccinated HCP. Each two-fold rise in NAI antibody titers reduced the hazard of symptomatic infection by 42% (95% CI: 36%-48%) against B/Phuket and 23% (95% CI: 13%-33%) against B/Brisbane, adjusting for HAI titers. Conclusions NAI antibodies were a strong correlate of protection against symptomatic IBV infection, with protective effects independent of those from HAI antibodies. These findings suggest the use and standardization of neuraminidase content in influenza vaccines could provide broader protection against influenza.
Reference Key
openalex_W7167891545 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Skyler Rogers, Kelsey M. Sumner, Yangyupei Yang, Emileigh Johnson, Ran Balicer, Alon Peretz, D Greenberg, Avital Hirsch, Mark A. Katz, Florian Krammer, Arnold S. Monto, Emily T. Martin
Journal The Journal of infectious diseases
Year 2026
DOI
10.1093/infdis/jiag351
URL
https://doi.org/10.1093/infdis/jiag351
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.